Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: ​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth prüft Angebote zu außerbörslichen Paketerwerben von Aktien an der United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth prüft Angebote zu außerbörslichen Paketerwerben von Aktien an der United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth prüft Angebote zu außerbörslichen Paketerwerben von Aktien an der United Internet AG
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease


Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult

RPM to Announce Fiscal 2022 Second-Quarter Results on January 5, 2022
RPM to Announce Fiscal 2022 Second-Quarter Results on January 5, 2022


RPM International Inc. (NYSE: RPM) announced today that it will release its financial results for the fiscal 2022 second quarter ended November 30, 2021, before the stock market opens on Wednesday

Guidewire Announces NXT Level Technologies as New Consulting Alliance Partner
Guidewire Announces NXT Level Technologies as New Consulting Alliance Partner


Guidewire (NYSE: GWRE) announced that NXT Level Technologies, an insurance IT services provider specializing in Guidewire products, has joined Guidewire PartnerConnect as a Consulting alliance

Aurubis AG: Aurubis AG und Wärme Hamburg GmbH bauen größte Industriewärmeversorgung Deutschlands weiter aus
Aurubis AG: Aurubis AG und Wärme Hamburg GmbH bauen größte Industriewärmeversorgung Deutschlands weiter aus
Aurubis AG: Aurubis AG und Wärme Hamburg GmbH bauen größte Industriewärmeversorgung Deutschlands weiter aus
Aurubis AG: Aurubis AG and Wärme Hamburg GmbH to further expand Germany's largest industrial heat system
Aurubis AG: Aurubis AG and Wärme Hamburg GmbH to further expand Germany's largest industrial heat system
Aurubis AG: Aurubis AG and Wärme Hamburg GmbH to further expand Germany's largest industrial heat system
Eurofins Enhances Clinical and COVID-19 Testing Offering in Japan Through Acquisition of Genetic Lab Co.,Ltd.
Eurofins Enhances Clinical and COVID-19 Testing Offering in Japan Through Acquisition of Genetic Lab Co.,Ltd.


Eurofins Scientific (EUFI.PA), the global scientific leader in bioanalytical testing and a leader in clinical diagnostics testing, announces a share purchase agreement with Transgenic Inc

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor

DGAP-News: Stabilus S.A. confirms preliminary figures for FY2021 and proposes dividend of €1.25 per share
DGAP-News: Stabilus S.A. confirms preliminary figures for FY2021 and proposes dividend of €1.25 per share
DGAP-News: Stabilus S.A. confirms preliminary figures for FY2021 and proposes dividend of €1.25 per share
DGAP-News: Stabilus S.A. bestätigt vorläufige Zahlen für GJ2021 und schlägt Dividende von 1,25 € je Aktie vor
DGAP-News: Stabilus S.A. bestätigt vorläufige Zahlen für GJ2021 und schlägt Dividende von 1,25 € je Aktie vor
DGAP-News: Stabilus S.A. bestätigt vorläufige Zahlen für GJ2021 und schlägt Dividende von 1,25 € je Aktie vor
Vici Properties Inc. Declares Regular Quarterly Dividend
Vici Properties Inc. Declares Regular Quarterly Dividend


VICI Properties Inc. (NYSE: VICI) (“VICI Properties” or the “Company”) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.36 per share of common stock

DGAP-News: 1&1 signs contracts with Vantage Towers and 1&1 Versatel for roll-out of its mobile network and publishes forecast for fiscal year 2022
DGAP-News: 1&1 signs contracts with Vantage Towers and 1&1 Versatel for roll-out of its mobile network and publishes forecast for fiscal year 2022
DGAP-News: 1&1 signs contracts with Vantage Towers and 1&1 Versatel for roll-out of its mobile network and publishes forecast for fiscal year 2022
DGAP-News: 1&1 AG schließt Verträge mit Vantage Towers und 1&1 Versatel für den Rollout ihres Mobilfunknetzes und veröffentlicht Prognose für das Geschäftsjahr 2022
DGAP-News: 1&1 AG schließt Verträge mit Vantage Towers und 1&1 Versatel für den Rollout ihres Mobilfunknetzes und veröffentlicht Prognose für das Geschäftsjahr 2022
DGAP-News: 1&1 AG schließt Verträge mit Vantage Towers und 1&1 Versatel für den Rollout ihres Mobilfunknetzes und veröffentlicht Prognose für das Geschäftsjahr 2022
DGAP-News: United Internet announces 2022 outlook and contract signings for mobile network roll-out
DGAP-News: United Internet announces 2022 outlook and contract signings for mobile network roll-out
DGAP-News: United Internet announces 2022 outlook and contract signings for mobile network roll-out
DGAP-News: United Internet mit Ausblick 2022 und Vertragsabschlüssen zum Rollout des Mobilfunknetzes
DGAP-News: United Internet mit Ausblick 2022 und Vertragsabschlüssen zum Rollout des Mobilfunknetzes
DGAP-News: United Internet mit Ausblick 2022 und Vertragsabschlüssen zum Rollout des Mobilfunknetzes
DGAP-Adhoc: United Internet announces 2022 outlook
DGAP-Adhoc: United Internet announces 2022 outlook
DGAP-Adhoc: United Internet announces 2022 outlook
AMN Named Among Top Corporate Boards in Diversity, Equity, and Inclusion Awards
AMN Named Among Top Corporate Boards in Diversity, Equity, and Inclusion Awards


The AMN Healthcare Board of Directors is one of 10 boards nationwide named as best of the best and finalists for the 2021 National Association of Corporate Directors (NACD) Diversity, Equity &amp

DGAP-Adhoc: Stabilus S.A.: Management Board and Supervisory Board propose dividend of €1.25 per share for fiscal year 2021
DGAP-Adhoc: Stabilus S.A.: Management Board and Supervisory Board propose dividend of €1.25 per share for fiscal year 2021
DGAP-Adhoc: Stabilus S.A.: Management Board and Supervisory Board propose dividend of €1.25 per share for fiscal year 2021